News
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped sharply premarket on Monday before paring losses as Barclays revised its ...
This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...
The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...
The European Medicines Agency determined testing failed to prove Elevidys’ benefit and issued a negative opinion that could ...
The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback